Endopulse Ltd.

Endopulse Ltd. , based in Or-Yehuda, Israel, is dedicated to revolutionizing cardiac care with innovative medical devices designed to enhance diagnosis and treatment outcomes for cardiovascular conditions. Founded in 2025, Endopulse Ltd. specializes in developing advanced medical technologies for cardiac care.

The company has not undergone any notable pivots or changes in operations since its inception. It operates out of Or-Yehuda, Israel, and is focused solely on its core mission. The firm has engaged in a single funding round, raising an undisclosed amount of SEED funding from Peregrine Ventures in May 2025, which contributes to their growth strategy. EndoPulse is focused on developing a groundbreaking medical device aimed at transforming cardiac care.

The core product offering is a revolutionary technology designed to improve diagnosis and treatment outcomes for patients with cardiovascular conditions. While specific functional details remain under wraps due to the company's stealth mode operations, the anticipated applications include enhanced monitoring, diagnostic capabilities, and potential therapeutic interventions for a variety of cardiac ailments. EndoPulse targets a diverse client base, which may encompass hospitals, clinics, and healthcare providers seeking to adopt innovative cardiac care solutions. The geographical markets for this offering are expected to include North America, Europe, and select regions in Asia, aligning with areas known for advanced medical technology adoption.

EndoPulse's revenue model is structured around direct transactions with healthcare providers and institutions, potentially involving both B2B and direct-to-consumer sales avenues. The company's flagship product is positioned for acquisition through standard purchase agreements or leasing options, enhancing accessibility for healthcare facilities. Revenue generation may also include subscription-based models for ongoing software updates or service agreements related to their core medical device. While specific pricing plans for their offerings are not disclosed, the transaction structure is designed to accommodate varying client budgets, ranging from large hospital systems to smaller clinics.

This multi-faceted revenue approach ensures a sustainable financial framework for EndoPulse as it navigates the complex healthcare landscape. Endopulse Ltd. aims to expand its product portfolio with the introduction of new medical devices tailored for cardiac care, with anticipated launches scheduled for late 2025. The company plans to penetrate additional markets, focusing on North America and Europe by the end of 2026.

The recent SEED funding acquired in May 2025 will be strategically employed to support these product developments and facilitate market entry efforts.